Literature DB >> 468983

Specific radioimmunoassay of human beta-endorphin in unextracted plasma.

E Wiedemann, T Saito, J A Linfoot, C H Li.   

Abstract

With an antiserum against human beta-endorphin (beta-EP) crossreacting less than 2% with human beta-lipotropin (beta-LPH) by weight we have developed a radioimmunoassay that can detect 1 pg beta-EP in diluted raw plasma. In a.m. fasting plasma of 14 normal subjects beta-EP ranged from less than 5 to 45 pg/ml. beta-EP was elevated in untreated, but normal in successfully treated Cushing's disease; undetectable in a patient with adrenal adenoma; extremely high in Nelson's syndrome; and elevated in a patient with bronchogenic carcinoma before, but undetectable after tumor resection. In subjects with intact hypothalamic-pituitary-adrenal axis, beta-EP was undetectable after dexamethasone and increased after metyrapone administration and insulin-induced hypoglycemia. beta-EP concentration was considerably lower in serum than in simultaneously collected plasma, but increased in serum left unfrozen for several hours after clot removal. Thus, beta-EP behaves like a hormone responding to the same stimuli as ACTH and beta-LPH and blood appears to contain enzymes both generating and destroying immunoreactive beta-EP.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 468983     DOI: 10.1210/jcem-49-3-478

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  10 in total

Review 1.  Exercise and secondary amenorrhoea linked through endogenous opioids.

Authors:  M T Ruffin; R E Hunter; E A Arendt
Journal:  Sports Med       Date:  1990-08       Impact factor: 11.136

2.  Effects of bile salts on plasma concentration of beta-endorphin-like immunoreactivity in men.

Authors:  M Matsumura; I Shimizu; M Ohura; H Mori; S Saito
Journal:  Dig Dis Sci       Date:  1988-06       Impact factor: 3.199

3.  Cyproheptadine treatment in Cushing's disease.

Authors:  R Tanakol; F Alagöl; H Azizlerli; O Sandalci; T Terzioğlu; F Berker
Journal:  J Endocrinol Invest       Date:  1996-04       Impact factor: 4.256

4.  Beta endorphin selectively stimulates aldosterone secretion in hypophysectomized, nephrectomized dogs.

Authors:  H G Güllner; J R Gill
Journal:  J Clin Invest       Date:  1983-01       Impact factor: 14.808

5.  Immunoreactive beta-endorphin and adrenocorticotropin in human cerebrospinal fluid.

Authors:  K Nakao; S Oki; I Tanaka; K Horii; Y Nakai; T Furui; M Fukushima; A Kuwayama; N Kageyama; H Imura
Journal:  J Clin Invest       Date:  1980-12       Impact factor: 14.808

6.  Simultaneous assay of immunoreactive beta-lipotropin, gamma-lipotropin, and beta-endorphin in plasma of normal human subjects, patients with ACTH/lipotropin hypersecretory syndromes, and patients undergoing chronic hemodialysis.

Authors:  X Y Bertagna; W J Stone; W E Nicholson; C D Mount; D N Orth
Journal:  J Clin Invest       Date:  1981-01       Impact factor: 14.808

7.  Limited effects of beta-endorphin compared to loperamide or fentanyl in a neuroendocrine biomarker assay in non-human primates.

Authors:  Eduardo R Butelman; Brian Reed; Brian T Chait; Marek Mandau; Vadim Yuferov; Mary Jeanne Kreek
Journal:  Psychoneuroendocrinology       Date:  2008-01-02       Impact factor: 4.905

8.  Beta-lipotropin and beta-endorphin in physiological and surgical menopause.

Authors:  A R Genazzani; F Facchinetti; M G Ricci-Danero; D Parrini; F Petraglia; R La Rosa; N D'Antona
Journal:  J Endocrinol Invest       Date:  1981 Oct-Dec       Impact factor: 4.256

9.  beta-Endorphin: stability, clearance behavior, and entry into the central nervous system after intravenous injection of the tritiated peptide in rats and rabbits.

Authors:  R A Houghten; R W Swann; C H Li
Journal:  Proc Natl Acad Sci U S A       Date:  1980-08       Impact factor: 11.205

10.  Vasopressin stimulates release of beta-lipotropin and beta-endorphin in conscious rats as measured by radioimmunoassay of unextracted plasma.

Authors:  H Anhut; W Knepel; D Nutto; G Hertting
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1981-02       Impact factor: 3.000

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.